ストックスクリーナーアプリを入手
4.8484
0.85%
-0.0415
前日終値:
$4.8899
開ける：
$4.6784
24時間の取引高:
3,805
Relative Volume:
0.10
時価総額：
$7.20M
収益：
$8.62M
当期純損益:
$-6.15M
株価収益率:
-0.4396
EPS:
-11.03
ネットキャッシュフロー:
$-5.32M
1週間 パフォーマンス:
+4.27%
1か月 パフォーマンス:
+5.40%
6か月 パフォーマンス:
-3.23%
1年 パフォーマンス:
-46.13%
1日の値動き範囲:
$4.6784
$4.8792
1週間の範囲:
$4.6167
$5.28
52週間の値動き範囲:
$3.54
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
EVOK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
4.8484 | 7.20M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-06-22 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2019-03-05 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2018-03-08 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-10-19 | 再開されました | FBR & Co. | Buy |
| 2017-03-16 | 繰り返されました | Rodman & Renshaw | Buy |
| 2017-01-30 | アップグレード | Laidlaw | Neutral → Buy |
| 2017-01-05 | アップグレード | Rodman & Renshaw | Neutral → Buy |
| 2016-12-23 | 繰り返されました | Rodman & Renshaw | Neutral |
| 2016-07-19 | 繰り返されました | FBR Capital | Outperform |
| 2016-07-19 | ダウングレード | Noble Financial | Buy → Hold |
| 2016-07-18 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2016-03-16 | 開始されました | Northland Capital | Outperform |
| 2016-03-14 | 繰り返されました | Ascendiant Capital Markets | Buy |
| 2016-02-17 | 再開されました | FBR Capital | Outperform |
| 2014-12-03 | 繰り返されました | MLV & Co | Buy |
| 2014-11-07 | 開始されました | MLV & Co | Buy |
| 2014-04-22 | 開始されました | Laidlaw | Buy |
| 2013-11-19 | 開始されました | Aegis Capital | Buy |
すべてを表示
Evoke Pharma Inc (EVOK) 最新ニュース
Gastroparesis Market Expected to rise, 2034 | Vanda - openPR
Nantahala Capital Management, LLC Increases Stake in Evoke Pharm - GuruFocus.com
Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World
StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Nantahala Capital Management, LLC Reduces Stake in Evoke Pharma Inc - GuruFocus.com
Trane Technologies (TT) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com - Defense World
Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role in Market TransformationTechnavio - PR Newswire
Soaring Global Digestive and Intestinal Remedies Market: Key - openPR
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
Gastroparesis Pipeline Trends 2024: Clinical Trials, - openPR
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL) - Defense World
Saluda Medical secures $100m for Evoke System commercialisation - Yahoo! Voices
Gastroparesis Treatment Market Future Business Opportunities - openPR
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com - Defense World
Here’s Why Evoke Pharma, Inc. (NASDAQ:EVOK) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
Gastroparesis Treatment Market Investment Opportunities: A Guide to 2031 | Evoke Pharma, Inc., Processa - EIN News
10 Best Diabetes Stocks To Buy Under $10 - Insider Monkey
Head to Head Contrast: Northwest Biotherapeutics (OTCMKTS:NWBO) vs. Evoke Pharma (NASDAQ:EVOK) - Defense World
Thinking about buying stock in Agile Therapeutics, Evoke Pharma, Warner Bros Discovery, Nkarta, or Sky Harbour? - Marketscreener.com
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
First Trust Indxx Global Natural Resources Income ETF (NASDAQ:FTRI) Shares Sold by Sanctuary Advisors LLC - Defense World
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming - MSN
Financial Survey: Evoke Pharma (NASDAQ:EVOK) and Geron (NASDAQ:GERN) - Defense World
StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Siga Technologies (SIGA) Stock Surges Over 5% Amid Market Activi - GuruFocus.com
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail
Adeia Enters into Multi-Year IP License Agreement with Canon - The Manila Times
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, - openPR
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends - GlobeNewswire
New York-Based Tech Stock Finds Massive Mid-Week Success - The Globe and Mail
Gastroparesis Treatment Market Generated Opportunities, - openPR
EVOK (Evoke Pharma) 5-Day RSI : 40.08 (As of Dec. 05, 2024) - GuruFocus.com
EVOK (Evoke Pharma) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Gray Television (GTN-N) QuotePress Release - The Globe and Mail
Mercadolibre Inc (MELI-Q) QuotePress Release - The Globe and Mail
Paramount Global Cl B (PARA-Q) QuotePress Release - The Globe and Mail
Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® - GlobeNewswire
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
EVOK (Evoke Pharma) 5-Day RSI : 34.66 (As of Nov. 28, 2024) - GuruFocus.com
Dell Technologies Inc (DELL-N) QuotePress Release - The Globe and Mail
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
First Solar Inc (FSLR-Q) QuotePress Release - The Globe and Mail
Amentum Stock Is Leading the S&P 500. What We Know. - MSN
Mesenchymal Stem Cells (MSC) Market Set to Surpass USD 9.72 - GlobeNewswire
Diabetic Gastroparesis Pipeline 2024: Clinical Trials - openPR
EVOK (Evoke Pharma) Total Assets : $14.15 Mil (As of Sep. 2024) - GuruFocus.com
Diabetic Gastroparesis Treatment Market: Global Size, Share, - openPR
Evoke Pharma Inc (EVOK) 財務データ
収益
当期純利益
現金流量
EPS
0.25%
0.51%
大文字化:
|
ボリューム (24 時間):